Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis in the Real-World
Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis in the Real-World
This was a retrospective cohort study utilizing secondary data from IQVIA's open source pharmacy claims database (i.e., IQVIA LRx) selecting patients with prescription claims for ofatumumab or other DMTs of interest.
The date of first ofatumumab prescription claim or other DMT of interest was defined as the index date. No post-index requirements were imposed.
Patients were linked to IQVIA's open source medical claims databases (Dx) to obtain patient clinical characteristics.
The initial data were extracted in October 2020. The data and results were refreshed in April 2021 and July 2021 to allow for assessment of changes in characteristics at 6 and 9 months post-launch.
Inclusion Criteria:
Patients with ≥ 1 prescription for ofatumumab in the LRx/Dx database were included. The date of the first observed prescription within the index window served as the index date.
-. Patients with a diagnosis of COVID-19 or a COVID-19 vaccination any time during the study period.
Patients with linkage to the Dx database.
Exclusion criteria
- No exclusion criteria were applied to patients in the study.